iBio to Present at the 2013 Gateway Conference on September 10

SAN FRANCISCO, CA--(Marketwired - Sep 5, 2013) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of technology for both proprietary and biosimilar products for use in development and production of biologics, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.

Management is scheduled to present at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. They will discuss the company's market opportunity and its unique proprietary platform to produce biologics using transient gene expression in unmodified green plants for use in the development of vaccines.

For additional information or to schedule a one-on-one meeting visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to schedule@gateway-conference.com or call Justin Vaicek at (949) 574-3860.

About the Gateway Conference
The Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 exciting growth companies across a broad range of industries, from technology, business and financial services, digital media and clean-tech to consumer products, retail/e-commerce, life sciences and natural resources. For more information, visit www.gateway-conference.com.

The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.

About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.